Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Pharma Ltd.

www.aurobindo.com

Latest From Aurobindo Pharma Ltd.

US FDA Warning Letter Draws Indian Solvent Recycler Into Valsartan Crisis

Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.

Manufacturing Quality

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Two Weeks Remain To Enter Industry Awards

Firms now have until 23 August to enter the Global Generics & Biosimilars Awards 2019.

Generic Drugs Biosimilars

Aurobindo Expects Sandoz Completion ‘Very Soon’

Aurobindo Pharma says its billion-dollar purchase of Sandoz’s US business is on track for completion “very soon” as it announced net first-quarter net profit that rocketed by nearly 40%, powered by strong US sales.

Deals Sales & Earnings
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register